{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:53:55Z","timestamp":1768445635014,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T00:00:00Z","timestamp":1248739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s11739-009-0284-x","type":"journal-article","created":{"date-parts":[[2009,7,27]],"date-time":"2009-07-27T09:29:27Z","timestamp":1248686967000},"page":"381-388","source":"Crossref","is-referenced-by-count":20,"title":["Essential thrombocythemia: past and present"],"prefix":"10.1007","volume":"4","author":[{"given":"Fabrizio","family":"Fabris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,28]]},"reference":[{"key":"284_CR1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01891529","volume":"293","author":"E Epstein","year":"1934","unstructured":"Epstein E, Goedel A (1934) Hemorrhagische Thrombozythamie bei vascularer Schrumpfmilz (Hemorrhagic thrombocythemia with a vascular, sclerotic spleen). Virchows Archiv Pathos Anat Histopathol 293:233\u2013248","journal-title":"Virchows Archiv Pathos Anat Histopathol"},{"key":"284_CR2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJM195403182501103","volume":"250","author":"H Fanger","year":"1954","unstructured":"Fanger H, Lj CellaJr, Litchman H (1954) Thrombocythemia: report of three cases and review of literature. N Engl J Med 250:456\u2013461","journal-title":"N Engl J Med"},{"key":"284_CR3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood.V15.5.706.706","volume":"15","author":"FW Gunz","year":"1960","unstructured":"Gunz FW (1960) Hemorrhagic thrombocythemia: a critical review. Blood 15:706\u2013723","journal-title":"Blood"},{"key":"284_CR4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-9343(60)90136-4","volume":"28","author":"FL Ozer","year":"1960","unstructured":"Ozer FL, Traux WE, Miesch DC et al (1960) Primary hemorrhagic thrombocythemia. Am J Med 28:807\u2013823","journal-title":"Am J Med"},{"key":"284_CR5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W (1951) Some speculation on the myeloproliferative syndromes. Blood 6:372\u2013375","journal-title":"Blood"},{"key":"284_CR6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Faguet GB, Jacobson RJ et al (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in multipotent stem cell. Blood 58:916\u2013919","journal-title":"Blood"},{"key":"284_CR7","first-page":"177","volume":"23","author":"S Murphy","year":"1986","unstructured":"Murphy S, Iland J, Rosenthal D et al (1986) Essential thrombocythemia: clinical and laboratory characteristics at presentation. Semin Hematol 23:177\u2013192","journal-title":"Semin Hematol"},{"key":"284_CR8","first-page":"2202","volume":"14","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The world health organization (WHO) classification of the myeloid neoplasms. Blood 14:2202\u20132292","journal-title":"Blood"},{"key":"284_CR9","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","volume":"107","author":"RL Levine","year":"2006","unstructured":"Levine RL, Belisle C, Wadleigh M et al (2006) X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET\/MMM and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107:4139\u20134141","journal-title":"Blood"},{"key":"284_CR10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"284_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"284_CR12","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","volume":"106","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Teo SS, Buser AS et al (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signalling by the V617F mutation of Jak2. Blood 106:3374\u20133376","journal-title":"Blood"},{"key":"284_CR13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP et al (2005) A unique clonal Jak2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"284_CR14","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"},{"key":"284_CR15","doi-asserted-by":"crossref","unstructured":"Skoda R (2007) The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol 2007:1\u201310","DOI":"10.1182\/asheducation-2007.1.1"},{"key":"284_CR16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schawager SM et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131:208\u2013213","journal-title":"Br J Haematol"},{"key":"284_CR17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"284_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","volume":"32","author":"P Johansson","year":"2006","unstructured":"Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemostas 32:171\u2013173","journal-title":"Semin Thromb Hemostas"},{"key":"284_CR19","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","volume":"108","author":"ML Randi","year":"2007","unstructured":"Randi ML, Putti MC, Scapin M et al (2007) Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108:3600\u20133602","journal-title":"Blood"},{"key":"284_CR20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097","journal-title":"Blood"},{"key":"284_CR21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","volume":"82","author":"J Thiele","year":"2003","unstructured":"Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148\u2013152","journal-title":"Ann Hematol"},{"key":"284_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2007","unstructured":"Wilkins BS, Erber WN, Bareford D et al (2007) Bone marrow pathology in essential thrombocythemia: intra-observer reliability and utility for identifying disease subtypes. Blood 111:60\u201370","journal-title":"Blood"},{"key":"284_CR23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A (2005) Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol 128:275\u2013290","journal-title":"Br J Haematol"},{"key":"284_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia 22:905\u2013914","journal-title":"Leukemia"},{"key":"284_CR25","first-page":"169","volume":"4","author":"F Fabris","year":"1980","unstructured":"Fabris F, Randi M, Casonato A et al (1980) Platelet aggregation and thrombopheresis in thrombocythemia. Thromb Haemostas 4:169","journal-title":"Thromb Haemostas"},{"key":"284_CR26","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V et al (2007) Leucocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factor and JAK2 mutation status. Blood 109:2310\u20132313","journal-title":"Blood"},{"key":"284_CR27","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Evangelista V et al (2000) Polymorphonuclear leucocytes activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96:4261\u20134266","journal-title":"Blood"},{"key":"284_CR28","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","volume":"112","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Finazzi G, Antonioli E et al (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112:3135\u20133137","journal-title":"Blood"},{"key":"284_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell RJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med 353:33\u201345","journal-title":"N Engl J Med"},{"key":"284_CR30","doi-asserted-by":"crossref","unstructured":"Vannucchi A, AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 110:840\u2013846","DOI":"10.1182\/blood-2006-12-064287"},{"key":"284_CR31","first-page":"15","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A et al (2004) Practice guidelines for the therapy of essential thrombocythemia. Haematologica 89:15\u2013232","journal-title":"Haematologica"},{"key":"284_CR32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G et al (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556\u2013562","journal-title":"J Clin Oncol"},{"key":"284_CR33","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"JJ Kiladijan","year":"2008","unstructured":"Kiladijan JJ, Cervantes F, Leebeek FWG et al (2008) The impact of Jak2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 111:4922\u20134929","journal-title":"Blood"},{"key":"284_CR34","first-page":"76","volume":"7","author":"ML Randi","year":"1994","unstructured":"Randi ML, Rossi C, Barbone E et al (1994) Superior sagittal sinus thrombosis in 5 patients with essential thrombocythemia: a possible disease variant. Rev Iberoam Tromb Hemostasia 7:76\u201378","journal-title":"Rev Iberoam Tromb Hemostasia"},{"key":"284_CR35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.thj.6200137","volume":"2","author":"A Federici","year":"2001","unstructured":"Federici A, Rand JH, Mannucci PM (2001) Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J 2:358\u2013362","journal-title":"Hematol J"},{"key":"284_CR36","doi-asserted-by":"crossref","unstructured":"Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755\u2013761","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"284_CR37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1046\/j.1365-2141.2000.02239-7.x","volume":"110","author":"H Hasle","year":"2000","unstructured":"Hasle H (2000) Incidence of essential thrombocythemia in children. Br J Haematol 110:751","journal-title":"Br J Haematol"},{"key":"284_CR38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2000.01817.x","volume":"108","author":"ML Randi","year":"2000","unstructured":"Randi ML, Putti MC, Fabris F (2000) Features of essential thrombocythemia in childhood: study of five children. Br J Haematol 108:86\u201389","journal-title":"Br J Haematol"},{"key":"284_CR39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00043426-199909000-00005","volume":"21","author":"Y Dror","year":"1999","unstructured":"Dror Y, Zipursky A, Blanchette VS (1999) Essential thrombocythemia in children. J Ped Hematol Oncol 21:356\u2013363","journal-title":"J Ped Hematol Oncol"},{"key":"284_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.20105","volume":"43","author":"ML Randi","year":"2004","unstructured":"Randi ML, Putti MC, Pacquola E (2004) Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Pediatr Blood Cancer 43:1\u20134","journal-title":"Pediatr Blood Cancer"},{"key":"284_CR41","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/14656566.5.5.1009","volume":"5","author":"ML Randi","year":"2004","unstructured":"Randi ML, Putti MC (2004) Essential thrombocythemia in children: is a treatment needed? Exp Opin Pharmacother 5:1009\u20131014","journal-title":"Exp Opin Pharmacother"},{"key":"284_CR42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","volume":"110","author":"F Passamonti","year":"2007","unstructured":"Passamonti F, Ml Randi, Rumi E et al (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the Jak2 (617V>F) mutation. Blood 110:485\u2013489","journal-title":"Blood"},{"key":"284_CR43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","volume":"130","author":"C Harrison","year":"2005","unstructured":"Harrison C (2005) Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 130:153\u2013165","journal-title":"Br J Haematol"},{"key":"284_CR44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-996111","volume":"23","author":"M Griesshammer","year":"1997","unstructured":"Griesshammer M, Bangerter M, van Vliet HH (1997) Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemostas 23:371\u2013377","journal-title":"Semin Thromb Hemostas"},{"key":"284_CR45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124","journal-title":"N Engl J Med"},{"key":"284_CR46","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortellazo","year":"1995","unstructured":"Cortellazo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132\u20131136","journal-title":"N Engl J Med"},{"key":"284_CR47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09537100400020179","volume":"16","author":"ML Randi","year":"2005","unstructured":"Randi ML, Ruzzon E, Tezza F (2005) Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16:181\u2013184","journal-title":"Platelets"},{"key":"284_CR48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 110:577\u2013583","journal-title":"Br J Haematol"},{"key":"284_CR49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.0007-1048.2002.03367.x","volume":"116","author":"F Passamonti","year":"2002","unstructured":"Passamonti F, Malabarba L, Orlandi E et al (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. Br J Haematol 116:855\u2013861","journal-title":"Br J Haematol"},{"key":"284_CR50","first-page":"51","volume":"34","author":"RM Petitt","year":"1997","unstructured":"Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51\u201354","journal-title":"Semin Hematol"},{"key":"284_CR51","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","volume":"97","author":"EC Storen","year":"2001","unstructured":"Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863\u2013866","journal-title":"Blood"},{"key":"284_CR52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","volume":"21","author":"G Barosi","year":"2007","unstructured":"Barosi G, Besses C, Birgegard G et al (2007) A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21:277\u2013280","journal-title":"Leukemia"},{"key":"284_CR53","doi-asserted-by":"crossref","unstructured":"Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: results of a ELN consensus conference. Blood [e-pub ahead of print]","DOI":"10.1182\/blood-2008-09-176818"},{"key":"284_CR54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0284-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-009-0284-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0284-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:34:26Z","timestamp":1590021266000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-009-0284-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,28]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1007\/s11739-009-0284-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,28]]}}}